Bolanowski M, Milewicz A, Bohdanowicz-Pawlak A, Bednarek-Tupikowska G, Jedrzejak J A, Lancranjan I
Department of Endocrinology, Wrocław Medical Academy, Poland.
Endokrynol Pol. 1993;44(4):467-76.
A double blind, double dummy study on the efficacy, tolerability and safety of Parlodel LAR versus oral Parlodel was carried out in 13 hyperprolactinemic women. Six patients received active from of Parlodel LAR (1 intramuscular injection at a dose of 50 mg) and placebo for oral Parlodel simultaneously. Seven other patients received active form of Parlodel orally (up to 7.5 mg daily) and placebo for Parlodel LAR injection. In all patients the marked reduction in serum prolactin level was observed. In normalization of prolactinemia was achieved in 8 patients (2 LAR, 6 oral). Galactorrhea disappeared in 7 of 8 patients (4 LAR, 3 oral), menstrual bleeding occurred in 5 of 10 amenorrheic patients (3 LAR, 2 oral). Tumor shrinkage was shown in 1 case (oral therapy). The improvement of slightly narrowed visual field was documented in 3 cases (2 LAR, 1 oral). The adverse effect during the therapy were mild and transient. We conclude that both froms of bromocriptine are very useful for treatment of hyperprolactinemia but Parlodel LAR is better tolerated and more convenient in application because of its prolonged activity.
对13名高泌乳素血症女性进行了一项关于长效溴隐亭（Parlodel LAR）与口服溴隐亭（Parlodel）的疗效、耐受性和安全性的双盲、双模拟研究。6名患者同时接受长效溴隐亭的活性制剂（1次50毫克的肌肉注射）和口服溴隐亭的安慰剂。另外7名患者口服溴隐亭活性制剂（每日剂量达7.5毫克）和长效溴隐亭注射用安慰剂。所有患者血清泌乳素水平均显著降低。8名患者（2名接受长效制剂，6名接受口服制剂）实现了泌乳素血症正常化。8名患者中的7名（4名接受长效制剂，3名接受口服制剂）溢乳消失，10名闭经患者中的5名（3名接受长效制剂，2名接受口服制剂）出现月经出血。1例（口服治疗）出现肿瘤缩小。3例（2名接受长效制剂，1名接受口服制剂）记录到轻度狭窄视野有所改善。治疗期间的不良反应轻微且短暂。我们得出结论，两种形式的溴隐亭对高泌乳素血症的治疗都非常有用，但长效溴隐亭耐受性更好，且由于其作用持久，应用更方便。
